Prexton Therapeutics raises €8.7 million ($10 million) in a Series A round
Prexton Therapeutics announced the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital. MS Ventures, the company's founding investor, will also participate.
This first funding will help Prexton Therapeutics to develop novel small molecules that target the metabotropic Glutamate Receptor 4 (mGluR4) up to completion of Phase 1. This has the potential to improve motor complications in Parkinson’s disease patients. The compounds were originally licensed from Domain Therapeutics, a French biopharmaceutical R&D company specializing in G protein-coupled receptors (GPCRs).
In the course of this fundraising, Andreas Segerros of Sunstone and Raúl Martín-Ruiz of Ysios, will join the Board of Directors of Prexton. Jasper Bos will continue to represent MS Ventures.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.